LONDON, Sept. 11, 2017 (GLOBE NEWSWIRE) -- The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.
In this brand new 164-page report from Visiongain, you will receive 84 tables and 93 figures – all unavailable elsewhere.
The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Global Erythropoietin Market forecasts from 2017-2027
Revenue forecasts of global erythropoietin market, segmented by product type:
- Epoetin Alfa
- Epoetin Beta
- Darbepoetin Alfa
- Biosimilars
- Others
To view report sample pages please click on:
https://www.visiongain.com/Report/1858/Global-Erythropoietin-Market-Forecast-2017-2027
This section also discusses the leading drugs as well as SWOT analysis of each submarket.
• Revenue forecasts of global erythropoietin market, segmented by application:
- Anemia (Cancer and HIV Treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others
• Revenue forecasts of global erythropoietin API manufacturing market, segmented by contract manufacturing and in-house manufacturing
• Erythropoietin Leading Regional Market forecasts from 2017-2027 covering North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Forecast for each regional market is further segmented by product type, application and country:
- US
- Canada
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- China
- Japan
- India
- Rest of Asia-Pacific
- Brazil
- Mexico
- Rest of Latin America
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
To view report sample pages please click on:
https://www.visiongain.com/Report/1858/Global-Erythropoietin-Market-Forecast-2017-2027
• Assessment of selected leading companies that hold major market shares in the erythropoietin market:
- Amgen
- Johnson & Johnson
- Roche
- Biocon
- 3SBio
- Pfizer
- Kyowa Hakko Kirin Co Ltd
- LG Life Sciences Limited
- Intas Pharmaceuticals Ltd
- Novartis AG
Visiongain’s study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions.
Please email Sara Peerun to request a free overview of this important report. Email sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.
Companies listed in this report include:
Companies Listed
3SBio Inc.
Accord Healthcare Limited
Actavis
Akebia Therapeutics
Amgen
Astellas Pharma Inc
AstraZeneca
Bio Sidus SA
Biocon Ltd
Casa Marzam
Casa Saba
Chugai Pharmaceutical
Claes-Göran Östenson
Corvidia Therapeutics
DaVita Inc
Dr. Reddy's Laboratories
FibroGen
First Shanghai Investments Limited
Fresenius Medical Care North America (FMCNA)
Galenica
Germans Trias i Pujol Hospital
GlaxoSmithKline
H. Lundbeck A/S
Hoffmann-La Roche
Hospira
Janssen Biotech
Japan Chemical Research Pharmaceuticals Co., Ltd.
Johnson & Johnson
Kissei pharmaceuticals
Kosin University Gospel Hospital
Kyowa Hakko Kirin Co Ltd
LG Life Sciences Limited
NADRO
NovaQuest Co-Investment Fund I, L.P.
Novartis Institutes for BioMedical Research (NIBR)
Novartis Pharmaceuticals
NOXXON Pharma AG
Pfizer
Proveedora de Medicamentos
RPG Life Sciences
Sandoz
Sirton Pharma
Stada
Stem Cell Therapeutics Corp.
Teva Pharmaceutical Industries Ltd.
UBI Pharma Inc.
Vifor Pharma
Please email Sara Peerun to request a free overview of this important report. Email sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.